PURPOSE: The goal of this pilot study was to explore the feasibility of 89Zr-labeled J591 monoclonal antibody positron-emission tomography (PET) of localized prostate cancer (PCa).
MATERIALS AND METHODS: Prior to scheduled radical prostatectomy, eleven patients were injected intravenously with 89Zr-J591 followed 6 days later by whole-body PET. Patients underwent surgery the day after imaging and the specimens were imaged by ex vivo micro-PET and custom 3 Tesla magnetic resonance scanner coil. PET imaging studies and histopathology were correlated.
RESULTS: Median age was 61 years (range, 47-68 years), median PSA was 5.2 ng/mL (3.5-12.0 ng/mL), and median biopsy Gleason score of the 11 index lesions was 7 (range, 7-9). On histopathology, a total of 22 lesions were identified. Median lesion size was 5.5 mm (range, 2-21 mm) and median post-RP Gleason score was 7 (range, 6-9). On in vivo PET, 8 of 11 index lesions were identified (72.7%). Lesion identification improved with increasing lesion size for in vivo (p< 0.0001) and ex vivo PET imaging (p< 0.0001), and increasing Gleason score (ex vivo PET imaging, p=0.01; in vivo, p=0.14). SUV appeared to correlate with increased Gleason score but was not significant (p=0.19).
CONCLUSIONS: This is the first report describing 89Zr-J591/PSMA PET imaging in localized PCa. In this setting, 89Zr-J591-PET binds to tumor foci in situ and identifies primarily Gleason ≥7 and larger sized tumors, likely corresponding to clinically significant disease warranting definitive therapy. Future work is planned in a larger clinical validation trial to better define the utility of 89Zr-J591-PET in localized PCa.
Written by:
Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. Are you the author?
Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Reference: J Urol. 2013 Oct 14. pii: S0022-5347(13)05648-6.
doi: 10.1016/j.juro.2013.10.041
PubMed Abstract
PMID: 24135437
UroToday.com Prostate Cancer Section
